Medtronic to Acquire Scientia Vascular for $550 Million to Strengthen Neurovascular Portfolio

Author | Dongtai

Medtronic Boosts Neurointervention.

01

5.5Billion US Dollars

Medtronic Announces AcquisitionScientia Vascular

Local time3Month10Day，MedtronicAnnouncementWill AcquireScientia Vascular，The latterTechnologies with critical innovations in the neurovascular field.The Value of This Acquisition5.5Billion US dollars（Equivalent to approximately RMB37.75100 million yuan), there may be undisclosed performance bonuses and milestone payments after the acquisition is completed.

This acquisition is expected to be completed by2027Completed in the first half of the fiscal year, but it is subject to regulatory approval and other closing conditions. This acquisition is expected to benefit Medtronic.2027 The impact on adjusted earnings per share for the fiscal year will be minimal, followed by earnings growth.

Scientia VascularIs a company located inUnited StatesA private enterprise in Utah with approximately310Name. The companyR&DCatheter products,Capable of providing simple and efficient treatment for complex neurovascular diseasesSolution。Scientia VascularGuidewire and Catheter Product SeriesAlsoCan be seamlessly integrated with Medtronic's existing neurovascular products.

Nowadays, StrokeHas becomeThe Third Leading Cause of Death and Disability Worldwide，Globally, every year, there are120010,000 people suffer from strokes. Compared with blood vessels in other parts of the body, the structure of cerebral blood vessels is extremely complex and tortuous, posing significant challenges for doctors to reach the location of vascular occlusion or aneurysms. Inaccessible vessel locations may delay treatment and affect the success rate of surgery.

Scientia VascularNew Type ofTechnologyThe platform aims to solve these problems by optimizing the navigation of complex anatomical structures and simplifying neurovascular surgical procedures, thereby improving the efficiency of interventional surgeries.

Linnea Burman, Senior Vice President and President of Medtronic's Neurovascular business, said that Medtronic is very pleased to acquire Scientia Vascular to accelerate value innovation in the field of neurovascular treatment.

"This acquisition gives Medtronic a complete product portfolio, laying a solid foundation for Medtronic and providing a strong position for addressing bleeding..."StrokeAnd Acute IschemicStrokeProvide strong support for treatment. Medtronic's leading therapies andScientia VascularLeading Interventional ProductsTheThe combination will be extremely powerful, and we look forward to bringing better treatment outcomes to patients around the world."The above-mentioned person stated."

Recently,MedtronicPublishedItsAs of1Month23DayThe2026Fiscal YearQ3Financial Performance。2026YearQ3Revenue reached90Billion USD, reported growth8.7%`, Organic Growth`6.0%, Exceeding Third Quarter Expectations50A basis point.

Among them,Cardiovascular Products Department Revenue34.57 Billion USD (+13.8%), Neuroscience Products Department Revenue25.58Billion US dollars (+4.1%), Medical Surgical Products Division Revenue21.73Billion US dollars (+4.9%), Diabetes Business Revenue7.96Billion USD (+14.8%）。

02

Giant Medical Device Companies Race to Increase Investment

Is Neurointervention a Good Business?

Just this year1Month,BossScientia Vascular AnnouncesHeavyweight News，In145Acquisition of Medical Technology Company for US$ BillionPenumbra. This is the second largest acquisition in Boston Scientific's history, and also in the medical device fieldOpenThe first deal exceeding 10 billion US dollars in the yearAcquisition Case。

AcquisitionPenumbraWillEnables Boco to obtainMechanical Thrombectomy and Neurovascular InterventionA leading product in the field, driving advancements in cardiology and neurovascular areas.TheTechnologyAndProduct Matrix.

In recent years,Vascular System of the Nervous SystemThe overall incidence of the disease is on the rise.

Taking stroke as an example,According to the Global Burden of Disease StudyData,25 In the population aged above, the global lifetime stroke risk is as high as24.9%. From the perspective of regional distribution,The region with the highest risk is East Asia., the lifetime risk of stroke is38.8%, followed by Central Europe (31.7%), Eastern Europe (31.6%）。

According to data from Cai Xin Securities,Expected to2026Year and2032By the year, the number of stroke cases in China will increase to approximately604.7Medtronic (China) Co., Ltd.723.810,000 people。

Neurointervention is a minimally invasive medical technique primarily used to treat lesions affecting the blood vessels of the human nervous system.It is usually performed in digital subtraction angiography.(DSA)Performed under systemic support, utilizing intravascular catheterization techniques, and employing methods such as selective angiography, embolization, dilation angioplasty, mechanical thrombectomy, and drug delivery for the diagnosis and treatment of lesions. This technique offers advantages such as minimal invasiveness, rapid recovery, and fewer complications.

Interventional procedures rely heavily on medical devices.With the in-depth application of interventional therapy, the market for related medical devices will also continue to grow.

Grand View ResearchThe report shows,2024The global neurovascular devices market size was estimated at73.4billion USD, and is expected to2030Annual growth to102.8Billion US dollars.

In the Chinese market, neurointervention has ushered in new development opportunities. According to2025China Stroke CongressDisclosure Data,China Has Built Stroke Centers in Tertiary Hospitals Nationwide718Home, Secondary Hospital Stroke Center1550Home, Coverage320Various regions,1622Districts and counties.

At present, domestic companies are also actively exploring the neurointervention market, and the industry is in a stage of accelerated development. The main players in this field includeCineway Medical、GuChuang TongQiao、Minimally Invasive Brain Science、Peijia Medical、ScienTech Medicaletc.

This neurointervention competition is far from over.